TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.7795
+0.0033 (0.43%)
At close: Aug 21, 2026, 4:00 PM EDT
0.7774
-0.0021 (-0.27%)
After-hours: Aug 21, 2026, 7:30 PM EDT
TScan Therapeutics Employees
TScan Therapeutics had 138 employees as of June 30, 2026. The number of employees decreased by 72 or -34.29% compared to the same quarter last year.
Employees
138
Change
-72
Growth
-34.29%
Revenue / Employee
$51,529
Profits / Employee
-$852,986
Market Cap
52.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 138 | -72 | -34.29% | 138 | 0 |
| Mar 31, 2026 | 139 | -62 | -30.85% | 138 | 1 |
| Dec 31, 2025 | 142 | -53 | -27.18% | 142 | 0 |
| Sep 30, 2025 | 148 | -51 | -25.63% | 146 | 2 |
| Jun 30, 2025 | 210 | 22 | 11.70% | 208 | 2 |
| Mar 31, 2025 | 201 | 34 | 20.36% | 200 | 1 |
| Dec 31, 2024 | 195 | 41 | 26.62% | 194 | 1 |
| Sep 30, 2024 | 199 | 44 | 28.39% | 188 | 11 |
| Jun 30, 2024 | 188 | 39 | 26.17% | 175 | 13 |
| Mar 31, 2024 | 167 | 29 | 21.01% | 161 | 6 |
| Dec 31, 2023 | 154 | 16 | 11.59% | 154 | 0 |
| Sep 30, 2023 | 155 | 24 | 18.32% | 145 | 10 |
| Jun 30, 2023 | 149 | 31 | 26.27% | 135 | 14 |
| Mar 31, 2023 | 138 | 33 | 31.43% | 136 | 2 |
| Dec 31, 2022 | 138 | 33 | 31.43% | 137 | 1 |
| Sep 30, 2022 | 131 | 36 | 37.89% | 127 | 4 |
| Jun 30, 2022 | 118 | 43 | 57.33% | 115 | 3 |
| Mar 31, 2022 | 105 | 44 | 72.13% | 104 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 113 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| Filana Therapeutics | 20 |
| Instil Bio | 17 |
| Edesa Biotech | 17 |
| Apollomics | 14 |
| Hyperion DeFi | 9 |
TCRX News
- 5 days ago - TScan Therapeutics reports Q2 EPS (23c), consensus (20c) - TheFly
- 10 days ago - TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - TScan Therapeutics Earnings release: Q2 2026 - Filings
- 10 days ago - TScan Therapeutics Quarterly report: Q2 2026 - Filings
- 24 days ago - TScan Therapeutics doses first patient in ALLOHA-2 trial - TheFly
- 24 days ago - TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies - GlobeNewsWire
- 7 weeks ago - TScan Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 2 months ago - TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire